25 completed, 19 recruiting, 7 active not recruiting, 4 not yet recruiting. 37 Phase 2, 31 Phase 1, 12 Phase 3.
Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-10-12 | 2026-11-06 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-11-12 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment Lurbinectedin, Radiation Therapy - Small Cell Lung Carcinoma | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 | 2025-12-31 | 2026-06-16 |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer ABBV-706, Atezolizumab, Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | AbbVie | 180 | 2025-11-25 | 2026-10-27 |
| Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS Lurbinectedin, Irinotecan - Desmoplastic Small Round Cell Tumor | Phase 2 | Recruiting | Italian Sarcoma Group | 20 | 2025-11-21 | 2026-11-03 |
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Serplulimab, Lurbinectedin, Carboplatin - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Guangzhou Institute of Respiratory Disease | 30 | 2024-12-01 | 2026-06-08 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC Lurbinectedin, Irinotecan, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Recruiting | Luye Pharma Group Ltd. | 180 | 2024-09-14 | 2024-12-12 |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2024-06-13 | 2026-11-12 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer Lurbinectedin, Dostarlimab - Endometrial Cancer | Phase 1 / Phase 2 | Withdrawn | Vall d'Hebron Institute of Oncology | 2024-05-01 | 2025-04-01 |
Showing 20 of 67. Sign in to see all of them.
Small Cell Lung Carcinoma (28) · Neoplasms (7) · Lung Neoplasms (6) · Breast Neoplasms (4) · Ovarian Neoplasms (4) · Sarcoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Neuroendocrine Tumors (3) · Sarcoma, Ewing (3) · Colorectal Neoplasms (2) · Desmoplastic Small Round Cell Tumor (2) · Mesothelioma (2) · Neoplasm Metastasis (2) · Adenoma, Islet Cell (1)
PharmaMar (20) · Jazz Pharmaceuticals (5) · AbbVie (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Luye Pharma Group Ltd. (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · AdventHealth (1) · Amgen (1) · Antonio Calles Blanco (1) · Children's Hospital of Philadelphia (1) · Daiichi Sankyo (1) · ERLINDA M GORDON (1) · Emory University (1)
United States (42) · Spain (26) · Italy (13) · Germany (12) · Belgium (11) · France (11) · Switzerland (10) · United Kingdom (10) · China (9) · Poland (9) · South Korea (9) · Canada (8) · Greece (7) · Hungary (7) · Austria (6)
Rubin Lubomirov, MD, PhD (2) · Alberto A Chiappori, MD (1) · Anastasios Dimou, MD (1) · Andrea B Apolo, M.D. (1) · Andres Poveda, MD (1) · Anish Thomas, M.D. (1) · Antonio Calles (1) · Erkut Borazanci, MD (1) · Erlinda M Gordon, MD (1) · Federica Grosso, MD (1) · Gregory Cote, M.D. Ph.D (1)
PMID 33914350, PMID 40963055, PMID 24563480, PMID 30240327, PMID 31896519, PMID 32085891, PMID 32224306, PMID 33096421, PMID 33704620, PMID 34453241, PMID 34521554, PMID 34739582, PMID 35486638, PMID 35830841, PMID 36037567, PMID 36252599, PMID 37407274, PMID 37491889, PMID 37556023, PMID 38351146, PMID 38964333, PMID 39490738, PMID 39530627, PMID 39932221, PMID 39938593, PMID 40116623, PMID 40473449, PMID 41055143, PMID 41791703, PMID 42081171, PMID 42377743
2023 (2), 2025 (2), 2017 (1), P30CA138292 (1)